
zzso zzso zzso zzso signaling through zzso zzso including zzso zzso zzso zzso zzso and zzso zzso is a key driver of multiple zzso The simultaneous zzso of multiple zzso zzso may increase zzso activity and minimize clinical resistance compared with a single zzso zzso 

We investigated the detailed pharmacology and zzso activity of the novel clinical drug candidate zzso an oral zzso zzso zzso zzso Gene expression zzso studies were undertaken to characterize the molecular mechanisms of action of zzso 

zzso caused substantial blockade of zzso zzso zzso zzso and zzso zzso zzso and induced zzso in a concentration and zzso manner in cancer cells with clinically relevant genetic defects in zzso and in zzso zzso efficacy in zzso zzso zzso breast, zzso zzso human prostate cancer, and zzso zzso zzso tumor zzso was zzso We show for the first time that induction of zzso zzso at zzso zzso by zzso as reported for other zzso zzso of zzso is not a zzso relevant zzso zzso Gene expression studies showed that zzso has a zzso effect on zzso zzso whereas the selective zzso inhibitor zzso zzso zzso zzso zzso of upstream regulators including zzso and zzso as a result of zzso feedback zzso was zzso 

The clinical candidate zzso is a novel oral zzso zzso inhibitor with potent zzso and zzso activity, which shows a distinct mechanism of action from other zzso zzso zzso will now be assessed in a zzso phase I zzso 

